• June 3-6, 2024
  • San Diego Convention Center, California



Oxford Biotherapeutics

Wednesday, June 05, 2024
Company Presentation
Company Presentation Theater 1
Oxford BioTherapeutics (OBT) is a clinical stage oncology company with a pipeline of first-in-class antibody-based therapies targeting indications of high, unmet need. Our proprietary, proteomic target discovery platform, OGAP®, is used to identify novel oncology protein targets for ADC, CAR-T, IO and bispecific therapeutic modalities for our collaborators and internal pipeline. We offer fully integrated ADC discovery and development, from target discovery through to IND enabling. OBT’s pipeline and development capabilities have been validated through multiple strategic partnerships including with world leaders in bispecific, ADC and CAR-T development such as Boehringer Ingelheim, ImmunoGen, Genmab, Kite, Amgen and others. OBT has a strong oncology focused management team and board with significant experience in developing IO and antibody-based therapies.
Oxford Biotherapeutics
Company Website: http://www.oxfordbiotherapeutics.com/
Lead Product in Development: Our lead asset, OBT076, is an innovative Antibody Drug Conjugate (ADC) with a potential dual mechanism of action. OBT076 targets the CD205 receptor on tumor cells as well as certain immune suppressive cells in high-risk cancer patients. The CD205 receptor is highly overexpressed in solid and liquid tumors with high unmet need including gastric, lung and ovarian cancer. OBT076 is demonstrating activity as a monotherapy. In addition, OBT076 can also act as a ‘primer’ re-engaging the patient’s immune system while at the same time targeting cancer cells. A maximum tolerated dose has been determined for OBT076 and the asset has shown promising early signs of clinical activity. It is currently being evaluated in Phase 1b expansion cohorts in multiple solid tumor indications. OBT is also planning combination trials for OBT076. OBT is responsible for the full development, approval and commercialization of OBT076 in North America and Japan. For oncology indications outside these territories OBT has out-licensed OBT076 to Menarini. Click here for Clinical Trials information.
Number Of Unlicensed Products (For Which You Are Seeking Partners): multiple oncology programs in various stages of development

Company HQ City

San Jose

Company HQ State


Company HQ Country

United States

CEO/Top Company Official

Christian Rohlff, PHD

Development Phase of Primary Product

Phase I
Primary Speaker
Mattthew Metzger
Program, Alliance and Business Development Manager
Oxford Biotherapeutics
Back to Session List

white squarewhite


Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.